Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers

Lung Cancer

Volumn 88, Issue 1, 2015, Pages 108-111

  Rangachari, Deepa ^a   Yamaguchi, Norihiro ^a   VanderLaan, Paul A ^a   Folch, Erik ^a   Mahadevan, Anand ^a   Floyd, Scott R ^a   Uhlmann, Erik J ^a   Wong, Eric T ^a   Dahlberg, Suzanne E ^b   Huberman, Mark S ^a   Costa, Daniel B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

ALK; Brain metastases; Central nervous system; CNS; EGFR; Lung cancer; Mutation; NSCLC; Rearrangement

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EGFR PROTEIN, HUMAN; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; FEMALE; GENE MUTATION; GENE REARRANGEMENT; GENOTYPE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; BRAIN TUMOR; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY; NONPARAMETRIC TEST; PATHOLOGY; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STATISTICS, NONPARAMETRIC;

EID: 84924579040     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.01.020     Document Type: Article

References (16)

1. Nayak L., Lee E.Q., Wen P.Y. Epidemiology of brain metastases. Curr Oncol Rep 2012, 14:48-54.
2. Shi A.A., Digumarthy S.R., Temel J.S., Halpern E.F., Kuester L.B., Aquino S.L. Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer?. J Thorac Oncol 2006, 1:205-210.
3. Heon S., Yeap B.Y., Britt G.J., Costa D.B., Rabin M.S., Jackman D.M., et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res 2010, 16:5873-5882.
4. Barnholtz-Sloan J.S., Sloan A.E., Davis F.G., Vigneau F.D., Lai P., Sawaya R.E. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004, 22:2865-2872.
5. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
6. Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crino L., Ahn M.J., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368:2385-2394.
7. Gerber D.E., Gandhi L., Costa D.B. Management and future directions in non-small cell lung cancer with known activating mutations. Am Soc Clin Oncol Educ Book 2014, e353-e365.
8. VanderLaan P.A., Yamaguchi N., Folch E., Boucher D.H., Kent M.S., Gangadharan S.P., et al. Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. Lung Cancer 2014, 84:39-44.
9. Yamaguchi N., VanderLaan P.A., Folch E., Boucher D.H., Canepa H.M., Kent M.S., et al. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. Lung Cancer 2013, 82:31-37.
10. Fine J.P., Grayzel D. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
11. Doebele R.C., Lu X., Sumey C., Maxson D.A., Weickhardt A.J., Oton A.B., et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 2012, 118:4502-4511.
12. Hendriks L.E., Smit E.F., Vosse B.A., Mellema W.W., Heideman D.A., Bootsma G.P., et al. EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?. Lung Cancer 2014, 84:86-91.
13. Eichler A.F., Kahle K.T., Wang D.L., Joshi V.A., Willers H., Engelman J.A., et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol 2010, 12:1193-1199.
14. Costa D.B., Kobayashi S., Pandya S.S., Yeo W.L., Shen Z., Tan W., et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011, 29:e443-e445.
15. Heon S., Yeap B.Y., Lindeman N.I., Joshi V.A., Butaney M., Britt G.J., et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2012, 18:4406-4414.
16. Zimmermann S., Dziadziuszko R., Peters S. Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. Cancer Treat Rev 2014, 40:716-722.